This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Strength Seen in Outset Medical (OM): Can Its 15.0% Jump Turn into More Strength?
by Zacks Equity Research
Outset Medical (OM) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
FMS Stock Likely to Gain on New Optimization Plan FME Reignite
by Zacks Equity Research
Fresenius Medical Care unveils FME Reignite, targeting one billion euros in cost savings, tech upgrades and enhanced shareholder returns.
Outset Medical, Inc. (OM) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Outset Medical (OM) delivered earnings and revenue surprises of -234.02% and 7.49%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
American Well Corporation (AMWL) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
American Well (AMWL) delivered earnings and revenue surprises of 44.01% and 11.18%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
Does Outset Medical (OM) Have the Potential to Rally 71.66% as Wall Street Analysts Expect?
by Zacks Equity Research
The consensus price target hints at a 71.7% upside potential for Outset Medical (OM). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Wall Street Analysts Predict an 188.63% Upside in Outset Medical (OM): Here's What You Should Know
by Zacks Equity Research
The consensus price target hints at an 188.6% upside potential for Outset Medical (OM). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Bears are Losing Control Over Outset Medical (OM), Here's Why It's a 'Buy' Now
by Zacks Equity Research
Outset Medical (OM) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.
Outset Medical, Inc. (OM) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Outset Medical (OM) delivered earnings and revenue surprises of 13.95% and 6.05%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?
WAT Earnings & Sales Surpass Estimates in Q4, Shares Rise
by Zacks Equity Research
WAT's fourth-quarter 2024 results reflect strong pharma growth and robust gains across all regions. However, forex headwinds hurt.
Will iRhythm Technologies (IRTC) Report Negative Earnings Next Week? What You Should Know
by Zacks Equity Research
IRhythm Technologies (IRTC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Outset Medical, Inc. (OM) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
by Zacks Equity Research
Outset Medical (OM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Outset Medical, Inc. (OM) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
Outset Medical (OM) delivered earnings and revenue surprises of 7.14% and 6.22%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?
Outset Medical, Inc. (OM) Reports Q2 Loss, Misses Revenue Estimates
by Zacks Equity Research
Outset Medical (OM) delivered earnings and revenue surprises of -9.30% and 12.18%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Butterfly Network, Inc. (BFLY) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Butterfly Network (BFLY) delivered earnings and revenue surprises of 50% and 7.11%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
10x Genomics (TXG) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
by Zacks Equity Research
10x Genomics (TXG) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Schrodinger, Inc. (SDGR) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Schrodinger (SDGR) delivered earnings and revenue surprises of 12.94% and 17.78%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Will Outset Medical, Inc. (OM) Report Negative Earnings Next Week? What You Should Know
by Zacks Equity Research
Outset Medical (OM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Outset Medical (OM) Upgraded to Buy: What Does It Mean for the Stock?
by Zacks Equity Research
Outset Medical (OM) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Outset Medical, Inc. (OM) Reports Q1 Loss, Misses Revenue Estimates
by Zacks Equity Research
Outset Medical (OM) delivered earnings and revenue surprises of -7.55% and 7.80%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
Outset Medical (OM) Inks Multi-Year Deal to Boost Home Dialysis
by Zacks Equity Research
Outset Medical's (OM) latest agreement is likely to provide patients and caregivers access to innovative home dialysis with the Tablo Hemodialysis System.
Inspire (INSP) Surges 9.9%: Is This an Indication of Further Gains?
by Zacks Equity Research
Inspire (INSP) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.
Outset Medical, Inc. (OM) Expected to Beat Earnings Estimates: Should You Buy?
by Zacks Equity Research
Outset Medical, Inc. (OM) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
BD (BDX) Gears Up for Q4 Earnings: What's in the Offing?
by Zacks Equity Research
Continued strength in BD's (BDX) Life Sciences segment's base business is expected to have benefited fiscal fourth-quarter sales.
Analysts Estimate Olink Holding AB (publ) Sponsored ADR (OLK) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Olink Holding AB (publ) Sponsored ADR (OLK) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
After Plunging -62.36% in 4 Weeks, Here's Why the Trend Might Reverse for Outset Medical, Inc. (OM)
by Zacks Equity Research
Outset Medical, Inc. (OM) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.